Other

City College of New York

Mediscience Technology Corp.

Guichen C Tang

Robert R Alfano

Yury Budansky

Leming M Wang

Asima Pradhan

Wubao Wang

Yang Pu

Kwong M Yoo

Laura A Sordillo

Bidyut B Das

Bidyut Das

Bidyut Baran Das

Stimson P Schantz

James Eastham

A rectal near infrared (NIR) scanning polarization imaging system uses NIR Photonic Prostatoscopy Analyzer (NIRPPA) for prostate cancer detection using light. The NIRPPA consists of a portable rectal NIR scanning polarization imaging unit and an optical fiber-based rectal probe capable of recording sets of 2D images of a prostate through rectum at different wavelengths and depths and obtaining a three dimensional (3D) image of the prostate and 3D locations of abnormal tissue inside the prostate. Diode lasers/light emission diodes (LEDs) with selected emitting wavelengths are used in the NIR spectral range from 650 nm to 2,400 nm corresponding to the four tissue optical windows (#I, 650 nm-950 nm; #II, 1,100 nm-1,350 nm; #III, 1,600 nm-1,870 nm; and #IV, 2,100 nm-2,300 nm). The fingerprint absorptions of water (HO), Oxyhemoglobin (HbO) and deoxyhemoglobin (Hb) in the prostate are used as native biomarkers for prostate cancer detection.

Near infrared photonic prostatoscopy analyzer

A method for monitoring the effects of a chemotherapeutic agent on a neoplasm medium. The method is premised on the discovery that chemotherapeutic agent, such as retinoic acid, affects the fluorescence spectroscopy of neoplasmic media and that such differences can be monitored, for example, by comparing the spectral profiles, spectral peaks, and spectral bandwidths of fluorescence at various wavelengths of the medium before and after administration of the chemotherapeutic agent. Differences in the excitation spectroscopy of the medium can also be used to monitor the effects of the agent.

Method for monitoring the effects of chemotherapeutic agents on

A method for determining if tissue is malignant as opposed to non-malignant (i.e., benign tumor tissue, benign tissue, or normal tissue). In one embodiment, the method comprises irradiating a human breast tissue sample with light at a wavelength of about 310 nm and measuring the time-resolved fluorescence emitted therefrom at about 340 nm. The time-resolved fluorescence profile is then compared to similar profiles obtained from known malignant and non-malignant human breast tissues. By fitting the profiles to the formula I(t)=A.sub.1 e.sup.(-t/.tau. 1.sup.) +A.sub.2 e.sup.(-t/.tau. 2.sup.), one can quantify the differences between tissues of various conditions. For example, non-malignant human breast tissues exhibit a slow component (.tau..sub.2) which is less than 1.6 ns whereas malignant human breast tissues exhibit a slow component (.tau..sub.2) which is greater than 1.6 ns. In addition, non-malignant human breast tissues exhibit a ratio of fast to slow amplitudes (A.sub.1 /A.sub.2) which is greater than 0.85 whereas malignant human breast tissues exhibit a ratio of fast to slow amplitudes (A.sub.1 /A.sub.2) which is less than 0.6. This technique can be used with different excitation and/or emission wavelengths, and can be applied to the detection of malignancies (or other abnormal states) in tissues other than human breast tissue.

Method for determining if tissue is malignant as opposed to

Biological material is characterized by illuminating the material with a beam of light, measuring light scattered from the material and then determining the condition of the material using the measurements. In one embodiment the angular line shape of the backscattered light is measured and then used to determine the scattering mean free path (1) and the absorption length (la) of the light scattered in the material to find out the condition of the material. These values so obtained are compared to values for a material whose condition is normal to determine if the condition of the material being examined is abnormal or normal. In another embodiment the temporal profile of the scattered pulse is used to determine (1) and (1a). The apparatus includes a laser for illuminating a section of material to be characterized, a streak camera for detecting light scattered from the material, a video camera for imaging the output of the streak camera, a computer for processing the output of the video camera to determine (1) and (1a) and a monitor for displaying the results to determine if the condition of the material being examined is normal or abnormal.

Noninvasive method and apparatus for characterizing biological materials

A method for determining if tissue is malignant as opposed to non-malignant (i.e., benign tumor tissue, benign tissue, or normal tissue), In one embodiment, the method comprises irradiating a human breast tissue sample with light at a wavelength of about 310 nm and measuring the time-resolved fluorescence emitted therefrom at about 340 nm. The time-resolved fluorescence profile is then compared to similar profiles obtained from known malignant and non-malignant human breast tissues. By fitting the profiles to the formula I(t)=A.sub.1 e(-t/.tau..sub.1)+A.sub.2 e(-t/.tau..sub.2) one can quantify the differences between tissues of various conditions. For example, non-malignant human breast tissues exhibit a slow component (.tau..sub.2) which is less than 1.6 ns whereas malignant human breast tissues exhibit a slow component (.tau..sub.2) which is greater than 1.6 ns. In addition, non-malignant human breast tissues exhibit a ratio of fast to slow amplitudes (A.sub.1 /A.sub.2) which is greater than 0.85 whereas malignant human breast tissues exhibit a ratio of fast to slow amplitudes (A.sub.1 /A.sub.2) which is less than 0.6. This technique can be used with different excitation and/or emission wavelengths, and can be applied to the detection of malignancies (or other abnormal states) in tissues other than human breast tissue.

A method and apparatus for distingishing cancerous tumors and tissue from benign tumors and tissue or normal tissue using native fluorescence. The tissue to be examined is excited with a beam of monochromatic light at 300 nanometers (nm). The intensity of the native fluorescence emitted from tissue is measured at 340 and 440 nm. The ratio of the two intensities is then calculated and used as a basis for determining if the tissue is cancerous as opposed to benign or normal. The invention is based on the discovery that when tissue is excited with monochromatic light at 300 nm, the native fluorescence spectrum over the region from about 320 nm to 600 nm is the tissue that is cancerous and substantially different from the native fluorescence spectrum that would result if the tissue is either benign or normal. The technique is useful in invivo and in vitro testing of human as well as animal tissue.

Growing community of inventors

Bronx, NY, United States of America

Guichen C Tang